Focus: Cancer Center Featured Story 2

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include a computer game that helps breast cancer survivors improve symptoms of peripheral neuropathy, a publicly available single-cell atlas of CD19 chimeric antigen receptor (CAR) T cells, new targets for TP53-mutant acute myeloid leukemia (AML), a preclinical target for preventing chemobrain, a blood test to help identify patients at higher risk of developing pancreatic cancer, and genomic insights to predict the risk of outcomes in patients with bone cancer.

• share
• favorite_border

Alejandro Aballay, Pharm.D., Ph.D., a national leader in immune signaling and graduate education, has been named dean of the MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, effective Jan. 2, 2024.

• share
• favorite_border

Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. October is Breast Cancer Awareness Month.

• share
• favorite_border

Robert A. Winn, MD, became president of the Association of American Cancer Institutes (AACI) today at the conclusion of the 2023 AACI/CCAF Annual Meeting in Washington, DC. He succeeds Caryn Lerman, PhD.

• share
• favorite_border

Cancer-related fatigue (CRF) is a debilitating yet all-too-common condition, which can severely affect quality of life for patients undergoing treatment. For those struggling with CRF, there have been no effective pharmaceutical treatments for the constellation of symptoms that together define the syndrome.

• share
• favorite_border

Investigators from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, the state’s leading cancer program and only National Cancer Institute-designated Comprehensive Cancer Center, investigated genomic alterations based on KRAS status to identify mutations in patients with KRAS wild type (WT).

• share
• favorite_border

IDRs comprise a large percentage of the human proteome and are particularly important for nuclear proteins that govern our genomic architecture and gene expression.

• share
• favorite_border

Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present new, novel, and expansive radiation oncology data from their clinical research program at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting, to be held in San Diego from October 1-4.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

• share
• favorite_border

Yale Cancer Center physicians, scientists, and trainees from Yale School of Medicine present new findings at the 65th annual American Society for Radiation Oncology (ASTRO) meeting from October 1-4 in San Diego, Calif.

• share
• favorite_border

What are some of the biggest challenges you face in caring for cancers in children? The biggest challenges are around supporting the parents. For the most part, children are resilient and upbeat.

• share
• favorite_border

• share
• favorite_border

While researchers continue to make advancements in cancer detection and treatment for breast cancer, one of the best ways to tackle the disease is through early detection and screening with mammography.

• share
• favorite_border

What young women should know about breast cancer and screening.

• share
• favorite_border

Researchers are working to improve outcomes for Black women with breast cancer – including through increased participation in clinical trials, which helps find better ways to prevent, diagnose and treat cancer.

• share
• favorite_border

California’s new Tobacco Cessation Policy Research Center will be located at UC Davis Comprehensive Cancer Center and funded with a $3.7 million state grant

• share
• favorite_border

A Ludwig Cancer Research study has for the first time exhaustively analyzed neutrophils that reside in brain tumors, detailing how the immune cells support brain cancer survival and how they’re turned by the tumor microenvironment into enablers of malignant growth.

• share
• favorite_border

The Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center has received a $10.4 million grant to study the eco-evolutionary dynamics responsible for non-small cell lung cancer growth and treatment resistance.

• share
• favorite_border

Evelyn Handel Zapata, PharmD, BCPS, BCOP, Senior Director of Drugs & Biologics Programs at the National Comprehensive Cancer Network® (NCCN®) was named a 40 Under 40 in Cancer: Emerging Leader; launches new resources for a type of pediatric lymphoma.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.

• share
• favorite_border

MD Anderson today broke ground on a 600,000-square-foot facility intended to anchor the institution’s expansive south campus research park. The building was purposefully built to enable collaborative science and impactful breakthrough discoveries that will accelerate efforts to end cancer.

• share
• favorite_border

In exploring an aspect of how killer T cells generate the raw materials required for their proliferation, a Ludwig Cancer Research study has uncovered an unexpected link between the immune cells’ metabolism, regulation of gene expression, persistence and functional efficacy that could be exploited using existing drugs to improve cancer immunotherapy.

• share
• favorite_border

Regular and intense aerobic exercise may reduce the risk of colorectal cancer in patients with Lynch Syndrome (LS) by improving the immune system's ability to detect and remove potentially harmful cells, according to researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

What advances have made the biggest impact in the treatment of patients with thyroid cancer over the last five years, and what is the outlook for thyroid cancer in the next five years? Molecular testing (MT) to examine somatic changes has become an important adjunct in the diagnosis and treatment of many cancers.

• share
• favorite_border

Prostate screening is a critical part of early diagnosis. How would you encourage a man reading this to see his doctor to begin prostate screenings? The decision to screen for prostate cancer is highly individualized, considering each man’s personal risk, race, as well as other potential health conditions.

• share
• favorite_border

As we honor lymphoma awareness month, what do you want our patients and families to pause and remember?Lymphoma is a disease which can strike any one of us, young and old, at any time.

• share
• favorite_border

Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective in younger patients, highlighting the need for further investigation into the impact of aging on the body’s ability to respond to treatment.

• share
• favorite_border

The Cancer Research Institute and the Lustgarten Foundation Announce INSPIRE Partnership to Jointly Support Pancreatic Cancer Immunotherapy Research 

• share
• favorite_border

Moffitt Cancer Center has been awarded a four-year, $3 million grant from the Department of Defense’s Congressionally Directed Medical Research Programs to develop new treatments for rare melanomas, including uveal melanoma. The grant will fund two projects aimed at advancing targeted alpha-particle therapies.

• share
• favorite_border

NCCN 2023 Annual Congress: Hematologic Malignancies features expert perspectives on developments in blood cancer treatment, including NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Updates, CAR T-Cell therapy, BTK Inhibitors, Bispecific T-Cell Engagers, and More. The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square.

• share
• favorite_border

Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) today announced a transformative gift from the Commonwealth Foundation for Cancer Research to benefit the Center for Experimental Therapeutics, a multidisciplinary research and drug development group at MSK.

• share
• favorite_border

The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—presented new recommendations for screening and addressing health-related social needs (HRSN) in people with cancer during a policy summit in Washington, D.C.

• share
• favorite_border

Fred Hutchinson Cancer Center will serve as the national coordinating center for a new epidemiological cohort study among Asian Americans, Native Hawaiians and Pacific Islanders (AsA-NHPI). Fred Hutch was awarded a seven-year, $38.7 million National Institutes of Health (NIH) grant to coordinate the effort to gather important health information on these populations, which are underrepresented in biomedical research.

• share
• favorite_border

Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation exposure to the heart and lungs, according to researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

Treatment planning for lung cancer can often be complex due to variations in assessing immune biomarkers. In a new study, Yale Cancer Center researchers at Yale School of Medicine used artificial intelligence (AI) tools and digital pathology to improve the accuracy of this process.

• share
• favorite_border

Although immunotherapies have shown promise in treating non-small cell lung cancer (NSCLC), many patients still do not respond well, and those who do may eventually develop resistance.

• share
• favorite_border

A new Yale Cancer Center study finds a targeted diet and exercise intervention could improve outcomes for women undergoing chemotherapy for breast cancer.

• share
• favorite_border

The immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.

• share
• favorite_border

New NCCN Guidelines for Patients: Blood Clots and Cancer provides much-needed education about recognizing and preventing the rarely-discussed cancer-associated consequence that is a major cause of death and morbidity

• share
• favorite_border

Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news.Reporting on wildfire smoke? Fred Hutch clinicians and researchers are available to their expertise.

• share
• favorite_border

New study in JNCCN from the University of Michigan found English speakers who call a hospital general information line were able to get information on next steps to access cancer care 94% of the time, compared to 38% for Spanish speakers and just 28% for Mandarin speakers.

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

By improving hospital care pathways, researchers from The University of Texas MD Anderson Cancer Center successfully reduced inpatient opioid use by 50% after pancreatic cancer surgery and cut the median opioid prescription volumes at discharge to zero.

• share
• favorite_border

MD Anderson and Panacea Venture announced the launch of Manaolana Oncology, a new company created to develop and advance antibody-based therapies against novel cancer targets.